Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Deramiocel
Other

Deramiocel

Tracked across 1 events · 287 articles · First seen Jul 27, 2026 · Last active Aug 02, 2026

Sentiment
-80
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
6 -80
Regulatory
Capricor Deramiocel FDA Setback Securities Class Actions
Paragon Therapeutics, a biotechnology company developing Deramiocel for Duchenne muscular dystrophy, faced a major regulatory setback. On July 27, 2026, the FDA released briefing documents ahead of an advisory committee meeting, raising concerns about post-hoc…
Impact: Deramiocel is Capricor's lead product candidate for Duchenne muscular dystrophy. The FDA's concerns about its clinical data threaten its approval prospects and the company's future.
Jul 27, 2026 · 287 articles
ERGEN INTELLIGENCE
Track Deramiocel live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.